Prognostic role of thyroid transcription factor-1 in stage III non-small cell lung cancer

Lung Cancer

Volumn 52, Issue 2, 2006, Pages 219-224

  Berghmans, T ^a   Mascaux, C ^a,b   Martin, B ^a   Ninane, V ^a   Sculier, J P ^a  

^a JULES BORDET INSTITUTE   (Belgium)

^b Hôpital Saint Pierre ^*

Author keywords

Non small cell lung cancer; Prognostic factors; Staging; Thyroid transcription factor 1

Indexed keywords

CREATININE; THYROID TRANSCRIPTION FACTOR 1;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KARNOFSKY PERFORMANCE STATUS; LUNG BIOPSY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN FUNCTION; SQUAMOUS CELL; STATISTICAL SIGNIFICANCE; TIME SERIES ANALYSIS;

ADULT; AGED; BELGIUM; BIOPSY; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; FOLLOW-UP STUDIES; HOMEODOMAIN PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; NUCLEAR PROTEINS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 33645994843     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2006.01.013     Document Type: Article

References (30)

1. Graziano S.L. Non-small cell lung cancer: clinical value of new biological predictors. Lung Cancer 17 Suppl. 1 (1997) S37-S58
2. Mountain C.F. Revisions in the international system for staging lung cancer. Chest 111 (1997) 1710-1717
3. Jassem J., Skokowski J., Dziadziuszko R., Jassem E., Szymanowska A., Rzyman W., et al. Results of surgical treatment of non-small cell lung cancer: validation of the new postoperative pathologic TNM classification. J Thorac Cardiovasc Surg 119 (2000) 1141-1146
4. Andre F., Grunenwald D., Pignon J.P., Dujon A., Pujol J.L., Brichon P.Y., et al. Survival of patients with resected N2 non-small-cell lung cancer: evidence for a subclassification and implications. J Clin Oncol 18 (2000) 2981-2989
5. Bollen E.C., Theunissen P.H., van Duin C.J., Drenth B.M., van Noord J.A., and Blijham G.H. Clinical significance of intranodal and extranodal growth in lymph node metastases of non-small cell lung cancer. Scand J Thorac Cardiovasc Surg 28 (1994) 97-102
6. Vansteenkiste J.F., De Leyn P.R., Deneffe G.J., Stalpaert G., Nackaerts K.L., Lerut T.E., et al. Survival and prognostic factors in resected N2 non-small cell lung cancer: a study of 140 cases. Leuven Lung Cancer Group. Ann Thorac Surg 63 (1997) 1441-1450
7. Inoue K., Sato M., Fujimura S., Sakurada A., Takahashi S., Usuda K., et al. Prognostic assessment of 1310 patients with non-small-cell lung cancer who underwent complete resection from 1980 to 1993. J Thorac Cardiovasc Surg 116 (1998) 407-411
8. Leong S.S., Rocha Lima C.M., Sherman C.A., and Green M.R. The 1997 International Staging System for non-small cell lung cancer: have all the issues been addressed?. Chest 115 (1999) 242-248
9. Berghmans T., Lafitte J.J., Thiriaux J., VanHoutte P., Lecomte J., Efremidis A., et al. Survival is better predicted with a new classification of stage III unresectable non-small cell lung carcinoma treated by chemotherapy and radiotherapy. Lung Cancer 45 (2004) 339-348
10. Sculier J.P., Paesmans M., Ninane V., Giner V., Bureau G., Lafitte J.J., et al. Evaluation of the TN sub-staging in patients with initially unresectable stage III non-small cell lung cancer treated by induction chemotherapy. The European Lung Cancer Working Party. Lung Cancer 22 (1998) 201-213
11. Kanters S.D., Lammers J.W., and Voest E.E. Molecular and biological factors in the prognosis of non-small cell lung cancer. Eur Respir J 8 (1995) 1389-1397
12. Sculier J.P., Paesmans M., Libert P., Bureau G., Dabouis G., Thiriaux J., et al. Facteurs pronostiques des cancers bronchiques non à petites cellules au stade avancé: expérience de l'European Lung Cancer Working Party]. Rev Mal Respir 14 (1997) 445-449
13. D'Amico T.A., Massey M., Herndon J.E., Moore M.B., and Harpole Jr. D.H. A biologic risk model for stage I lung cancer: immunohistochemical analysis of 408 patients with the use of ten molecular markers. J Thorac Cardiovasc Surg 117 (1999) 736-743
14. Pastorino U., Andreola S., Tagliabue E., Pezzella F., Incarbone M., Sozzi G., et al. Immunocytochemical markers in stage I lung cancer: relevance to prognosis. J Clin Oncol 15 (1997) 2858-2865
15. Pelosi G., Fraggetta F., Pasini F., Maisonneuve P., Sonzogni A., Iannucci A., et al. Immunoreactivity for thyroid transcription factor-1 in stage I non-small cell carcinomas of the lung. Am J Surg Pathol 25 (2001) 363-372
16. Puglisi F., Barbone F., Damante G., Bruckbauer M., Di L.V., Beltrami C.A., et al. Prognostic value of thyroid transcription factor-1 in primary, resected, non-small cell lung carcinoma. Mod Pathol 12 (1999) 318-324
17. Berghmans T., Meert A.P., Martin B., Ninane V., and Sculier J.P. Prognostic role of epidermal growth factor receptor in stage III non-small cell lung cancer. Eur Respir J 25 (2005) 329-335
18. Berghmans T., Mascaux C., Martin B., Ninane V., and Sculier J.P. Prognostic role of p53 in stage III non-small cell lung cancer. Anticancer Res 25 (2005) 2385-2389
19. Meert A.P., Martin B., Delmotte P., Berghmans T., Lafitte J.J., Mascaux C., et al. The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis. Eur Respir J 20 (2002) 975-981
20. Fabbro D., Di Loreto C., Stamerra O., Beltrami C.A., Lonigro R., and Damante G. TTF-1 gene expression in human lung tumours. Eur J Cancer 32A (1996) 512-517
21. Linnoila R.I., Jensen S.M., Steinberg S.M., Mulshine J.L., Eggleston J.C., and Gazdar A.F. Peripheral airway cell marker expression in non-small cell lung carcinoma. Association with distinct clinicopathologic features. Am J Clin Pathol 97 (1992) 233-243
22. Au N.H., Cheang M., Huntsman D.G., Yorida E., Coldman A., Elliott W.M., et al. Evaluation of immunohistochemical markers in non-small cell lung cancer by unsupervised hierarchical clustering analysis: a tissue microarray study of 284 cases and 18 markers. J Pathol 204 (2004) 101-109
23. Haque A.K., Syed S., Lele S.M., Freeman D.H., and Adegboyega P.A. Immunohistochemical study of thyroid transcription factor-1 and HER2/neu in non-small cell lung cancer: strong thyroid transcription factor-1 expression predicts better survival. Appl Immunohistochem Mol Morphol 10 (2002) 103-109
24. Myong N.H. Thyroid transcription factor-1 (TTF-1) expression in human lung carcinomas: its prognostic implication and relationship with wxpressions of p53 and Ki-67 proteins. J Kor Med Sci 18 (2003) 494-500
25. Saad R.S., Liu Y.L., Han H., Landreneau R.J., and Silverman J.F. Prognostic significance of thyroid transcription factor-1 expression in both early stage conventional adenocarcinoma and bronchioloalveolar carcinoma of the lung. Hum Pathol 35 (2004) 3-7
26. Shah L., Walter K.L., Borczuk A.C., Kawut S.M., Sonett J.R., Gorenstein L.A., et al. Expression of syndecan-1 and expression of epidermal growth factor receptor are associated with survival in patients with non-small cell lung carcinoma. Cancer 101 (2004) 1632-1638
27. Stenhouse G., Fyfe N., King G., Chapman A., and Kerr K.M. Thyroid transcription factor-1 in pulmonary adenocarcinoma. J Clin Pathol 57 (2004) 383-387
28. Tan D., Li Q., Deeb G., Ramnath N., Slocum H.K., Brooks J., et al. Thyroid transcription factor-1 expression prevalence and its clinical implications in non-small cell lung cancer: a high-throughput tissue microarray and immunohistochemistry study. Hum Pathol 34 (2003) 597-604
29. Barlesi F., Pinot D., Legoffic A., Doddoli C., Chetaille B., Torre J.P., et al. Positive thyroid transcription factor-1 staining strongly correlates with survival of patients with adenocarcinoma of the lung. Br J Cancer 93 (2005) 450-452
30. Meert A.P., Martin B., Verdebout J.M., Paesmans M., Lothaire P., Bosschaerts T., et al. Corrélation entre l'expression d'EGFR dans les biopsies et les pièces chirurgicales des cancers bronchiques. Rev Mal Respir 20 (2003) 347-353